EMEA-001716-PIP07-22 - paediatric investigation plan
Venglustat
PIPHuman
Key facts
- Active Substance
- Venglustat
- Therapeutic area
- Endocrinology-Gynaecology-Fertility-Metabolism
- Neurology
- Decision number
- P/0489/2023
- PIP number
- EMEA-001716-PIP07-22
- Pharmaceutical form(s)
- Chewable tablet
- Condition(s) / indication(s)
- Gaucher disease, type 2
- Gaucher disease, type 3
- Route(s) of administration
- Oral use
- Contact for public enquiries
Sanofi B.V.
E-mail: eumedinfo.gz@sanofi.com
Tel: +31 (0) 20 245 3917- Decision type
- P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
- Decision date